Feeling pressure to be an "AI company," Product Fruits' CEO initially pushed for AI integration across all internal processes. He later realized this was counterproductive, as forced adoption in areas where it didn't naturally fit led to nonsensical outcomes. True efficiency comes from targeted, not blanket, implementation.

Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

Many firms are stuck in "pilot purgatory," launching numerous small, siloed AI tests. While individually successful, these experiments fail to integrate into the broader business system, creating an illusion of progress without delivering strategic, enterprise-level value.

When boards pressure CEOs for AI, the result is often a centralized, consultant-led project disconnected from operations. These initiatives fail because they lack alignment and nobody understands how they work, creating skepticism for future efforts.

Marketing leaders pressured to adopt AI are discovering the primary obstacle isn't the technology, but their own internal data infrastructure. Siloed, inconsistently structured data across teams prevents them from effectively leveraging AI for consumer insights and business growth.

The most common failure in AI strategy is adhering to a linear, sequential planning process where each department creates its own strategy in isolation. AI's power lies in connecting disparate data sets across functions, which a siloed, 'baton-passing' approach inherently prevents.

Many firms engage in "innovation theatre," building a portfolio of impressive but isolated AI pilots. Without a unifying strategic architecture connecting them to core growth objectives, these initiatives remain islands that fail to scale, compound, or move overall enterprise performance.

Many pharma companies allow various departments to run numerous, disconnected AI pilots without a central strategy. This lack of strategic alignment means most pilots fail to move beyond the proof-of-concept stage, with 85% yielding no measurable return on investment.

Pharma companies engaging in 'pilotitis'—running random, unscalable AI projects—are destined to fall behind. Sustainable competitive advantage comes from integrating AI across the entire value chain and connecting it to core business outcomes, not from isolated experiments.